Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Marilyn Pike

Rheumatology Boston, MA Medical Doctor

NPI 1851372833 CMS profile 219458

55 Fruit St, Yaw 2100 Rheumatology Associates, Boston, MA 02114

Open in the dashboard

General payments

$1,449,068

146 records reported · program years 2019–2025

Research payments

$101,754

Paid to them · 5 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Marilyn Pike of Boston, MA is reported in the CMS Open Payments database as having received $1,449,068 across 146 general payments and $101,754 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $31,023 8
2024 General $114,392 26
2023 General $193,213 33
2022 General $223,152 16
2021 General $285,861 15
2021 Research $636 1
2020 General $329,862 27
2020 Research $67,098 2
2019 General $271,564 21
2019 Research $34,020 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Marilyn Pike
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Marilyn Pike were reported at $31,023. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Marilyn Pike Rheumatology median Middle half National median
2019 $271,564 $744 $153–$2,687 $163
2020 $329,862 $462 $98–$2,027 $114
2021 $285,861 $531 $101–$2,153 $132
2022 $223,152 $627 $125–$2,303 $149
2023 $193,213 $741 $145–$2,524 $160
2024 $114,392 $830 $166–$2,660 $164
2025 $31,023 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $793,661 54 payments
  2. Janssen Research & Development, LLC $330,999 29 payments
  3. AstraZeneca UK Limited $171,171 21 payments
  4. E.R. Squibb & Sons, L.L.C. $118,556 35 payments
  5. Ucb SA $34,682 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $1,429,988 132 payments
  2. Travel and Lodging $18,926 10 payments
  3. Food and Beverage $154 4 payments
Products named General payments · program years 2019–2025
  1. STELARA $330,925 27 payments
  2. SAPHNELO $148,171 17 payments
  3. SOTYKTU $102,985 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. E.R. Squibb & Sons, L.L.C. $101,754 5 payments

Records

151 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record